Disclaimer (Chrissie Fletcher)

Disclaimer (Chrissie Fletcher)

Impact of E9 Addendum to Chrissie Fletcher Industry (one of two EFPIA representatives on the ICH E9 Working Group) PSI/EFSPI 1-day scientific meeting 28-Sept-15 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1

Disclaimer (Chrissie Fletcher) The views expressed herein represent those of the presenter and do not necessarily represent the views or practices of Amgen, the views of the other Industry representatives on the ICH E9 working group, or the views of the general Pharmaceutical Industry. 2 Agenda

Impact of the new E9 addendum to Industry Feedback from EFSPI Statistics Leaders discussion High level results from international E9 survey Key issues debated in E9 WG (thus far!)

How addendum will align with E9 Important questions for you to consider Q&A 3 Impact to E9 addendum to Industry The new framework will o

Improve the way we design and plan clinical trials - Objectives Estimand(s) Primary analyses Sensitivity analyses o o o Optimise the way we conduct clinical trials - Data collection, patient follow-up Perform primary analyses aligned to objectives - Handling of non-adherence

Perform sensitivity analyses aligned to primary analyses - Robustness of estimand(s) 4 EFSPI Statistics Leaders feedback Potential bias seems to be underpinning the estimand discussion. o

contextualise in the rationale Range of examples would be appreciated to better help understanding the differences between estimands (incl. use of graphics) Defining what the role of sensitivity analyses is would be helpful The involvement of clinicians is very important as it is understood this is not just a statistical issue 5

International E9 survey Conducted May-June 2015 o Thanks to those who completed it! Collect views of current practice on what: o o o o

o Treatment effects are being estimated in clinical trials Awareness of relevant guidelines Techniques to minimise missing data Analysis choices for primary and sensitivity analyses Comments (lots of them!) 6 E9 survey demographics (N=1305)

7 E9 survey - demographics 8 E9 survey - demographics 9 E9 survey - demographics

10 Treatment effect being estimated in a primary analysis outcome/event trials 11 Treatment effect being estimated in a primary

analysis symptom trials 12 Try to collect data for patients who stop treatment but remain on study 13 Try to contact patients to prevent lost to follow up

14 Steps taken to prevent missing data 15 How much primary endpoint data attributed to study dropout

16 Methods for handling missing data in primary analyses 17 What influences your choice for handling missing data in primary analyses 18

Key issues debated in E9 WG Distinguishing between the various estimands Areas of E9 that would benefit from further clarification Developing laymans explanations Sharing case studies from all regions and how the choice of estimand contributed to regulatory decision making Exploring methodologies that align to each category

of estimand technical appendix 19 How addendum will align with E9 The addendum cannot conflict with any principles described in E9 The proposed framework may position some of the existing principles in E9 in a different way

There may be areas of E9 that require further clarification to fully align the addendum In the spirit of E9 the addendum will not be recommending statistical methods 20 Important questions for you to consider 1. 2.

3. 4. Does the definition of an estimand make sense? Does the proposed framework in the E9 addendum make sense? Do you have any concerns with the framework? How much of a difference is the proposed framework compared to how you currently design clinical trials? 5. What do you see as key challenges for introducing the framework?

6. How do you think clinicians will view estimands and the proposed framework? 21 References ICH concept paper (2014) E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials Lewis JA (1999) Statistical principles for clinical trials (ICH E9): An introductory note on an international guideline. Statistics in Medicine, 18: 1903-1904.

ICH Expert Working Group (1999) Statistical principles for clinical trials (ICH E9). Statistics in Medicine, 18: 1905-1942. National Research Council of the National Academies (2010) The Prevention and Treatment of Missing Data in Clinical Trials. Washington, D.C.: National Academies Press. EMA (2011), Guideline on Missing Data in Confirmatory Clinical Trials. ONeill RT and Temple R (2012) The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther, 91: 550-554. Little RJ, DAgostino R, Cohen M, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med, 367(14): 1355-1360.

A structured approach to choosing estimands and estimators in longitudinal clinical trials. C. H. Mallinckrodt et al. Pharmaceut. Statist. 2012, 11 456461 Missing Data: Turning Guidance Into Action. C. H. Mallinckrodt et al. Statistics in Biopharmaceutical Research 2013, Vol. 5, No. 4, 369-382 Choosing Appropriate Estimands in Clinical Trials. AK Leuchs et al. DIA Therapeutic Innovation & Regulatory Science. 2015 22

Recently Viewed Presentations

  • Parts of a Map - Westlake City School District

    Parts of a Map - Westlake City School District

    Parts of a Map * * * * * * * * Parts of a Map Most maps have the following elements, which are necessary to read and understand them Title The title explains the subject of the map and...
  • 11.4 Stressed Possessive Adjectives and Pronouns

    11.4 Stressed Possessive Adjectives and Pronouns

    Used with un/una, these possessives are similar in meaning to the English expression of mine/yours/etc. Juancho es un amigo mío. Juancho is a friend of mine. Stressed possessive adjectives must agree in gender and number with the nouns they modify.
  • Department of Agriculture Illinois State University Faculty and

    Department of Agriculture Illinois State University Faculty and

    Mission Statement. The mission of the Department of Agriculture at Illinois State University is to deliver the highest quality academic programs, prepare students for careers in the food and agriculture industry, conduct scholarly activities that are beneficial to the citizens...
  • Grickit - Virginia Tech

    Grickit - Virginia Tech

    --ahp All of the matrix calculations are implemented on the server so they can be completed with an HTTP call that has a correctly formatted payload --Grickit Management & Database interactions
  • Writing Strong Bullet Points AGENDA > Resume Basics

    Writing Strong Bullet Points AGENDA > Resume Basics

    Always start a bullet point with a strong verb, either present or past tense, not ending in -ing. Add adjectives to help clarify what you accomplished. Be sure not to make the statement a hyperbole . Usually to convey time,...
  • Arteries Blood Vessel Arterioles Ventricles Capillaries Heart! Atria

    Arteries Blood Vessel Arterioles Ventricles Capillaries Heart! Atria

    Distribution of Blood Figure 15-10 in textbook Control: 1) Para => HR 2) Sym => HR, Force Control: 1) Sym => r ( R) 2) Sym => r ( R) 3) myogenic control 4) paracrines and hormones fluid intake =>...
  • ppt_small_image

    ppt_small_image

    Committee Report Senate Academic Affairs Committee (SAAC) April 14, 2015 Derrek Dunn, Ph.D. School of Business and Technology * Overview of Curriculum and Course Proposals Course changes: (4) from Kinesiology (4) from Criminal Justice (3) from Social Sciences (1) from...
  • DCSL Research Overview - Purdue Engineering

    DCSL Research Overview - Purdue Engineering

    High-Level Context of Research. Dependability: Property that the computer system meets its specification despite the presence of faults. Faults can be due to natural causes (software bugs, defects in hardware)